From the weekly letter · 26 October 2026

Why cover this story this week?

Designing a smaller blocker of inflammation

Another molecular-design preprint targets IL-23, a signaling protein involved in inflammatory bowel disease and psoriasis. Existing antibodies against its p19 component are effective medicines, but the researchers are exploring much smaller proteins designed to obstruct the same receptor-binding surface. A conventional computational pipeline produced no reliably predicted interfaces among 972 designs. An interface-optimized method, BindCraft, performed substantially better on the researchers’ prediction metrics, yielding five lead candidates for closer analysis.

This is a computational result, not evidence of a new treatment. None of the candidates has yet been experimentally shown to bind or neutralize IL-23. The study also highlights a practical difficulty in protein engineering: apparently reassuring scores can reflect protein length or quirks of the prediction setup rather than a convincing molecular interface. Better scoring can improve the shortlist, but laboratory tests remain essential.

Editorial context written by AI from abstracts, not independent scientific validation. The kit and its verified quotes rely on the source paper, not on this letter.

Read the full letter →

Talk about a paper in public without overstating it: yours, one you are asked to comment on, or one you write about as a journalist.

  • Your paper: a draft release for your press office, the questions journalists will ask with what the paper lets you answer, the likely misreadings, a lay summary and a short thread.
  • Asked to comment: what the paper shows and does not, its strengths and weaknesses with their passages, and what would settle its main claim.
  • Writing about it as a journalist: reporting angles, the wording to check before publication, and the questions to ask the authors.
  • For everyone: findings with their passages checked word for word, the novelty set against the closest earlier papers, a hype check, figures with their credit, and researchers for an outside view who have not signed with the authors.

Discover Premium+ See an example kit